Salsalate: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(New page: In pharmacology, '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a medication which is a non-steroidal anti-inflammatory agent. Salsala...)
 
(duplicate ref)
 
(3 intermediate revisions by 2 users not shown)
Line 1: Line 1:
In [[pharmacology]], '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a [[medication]] which is a [[non-steroidal anti-inflammatory agent]].
{{subpages}}
In [[pharmacology]], '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a [[medication]] which is a [[non-steroidal anti-inflammatory agent]]. Salsalate is related to acetylsalicylic acid ([[aspirin]]), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]].


Salsalate may reduce the [[Glycosylated hemoglobin A|Glycosylated hemoglobin A1c]] in patients with [[diabetes mellitus type 2]].<ref name="pmid20231565">{{cite journal| author=Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al.| title=The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 6 | pages= 346-57 | pmid=20231565 | doi=10.1059/0003-4819-152-6-201003160-00004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20231565  }} </ref>
Salsalate may reduce the [[Glycosylated hemoglobin A|Glycosylated hemoglobin A1c]] in patients with [[diabetes mellitus type 2]].<ref name="pmid20231565">{{cite journal| author=Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al.| title=The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 6 | pages= 346-57 | pmid=20231565 | doi=10.1059/0003-4819-152-6-201003160-00004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20231565  }} </ref>
==Drug toxicity==
Tinnitus may happen, but is unlikely if the total daily dose is 3 grams or less.<ref name="pmid20231565"/>
Gastrointestinal toxicity is less than with other [[non-steroidal anti-inflammatory agent]]s.<ref name="pmid2181673">{{cite journal| author=Roth S, Bennett R, Caldron P, Hartman R, Mitchell C, Doucette M et al.| title=Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study. | journal=Semin Arthritis Rheum | year= 1990 | volume= 19 | issue= 4 Suppl 2 | pages= 11-9 | pmid=2181673 | doi= | pmc= | url= }} </ref><ref name="pmid2625689">{{cite journal| author=Lanza F, Rack MF, Doucette M, Ekholm B, Goldlust B, Wilson R| title=An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen. | journal=J Rheumatol | year= 1989 | volume= 16 | issue= 12 | pages= 1570-4 | pmid=2625689 | doi= | pmc= | url= }} </ref>


==References==
==References==
<references/>
<references/>

Latest revision as of 19:14, 1 September 2024

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

In pharmacology, salsalate, also called salicylsalicylic acid and disalicylic acid, is a medication which is a non-steroidal anti-inflammatory agent. Salsalate is related to acetylsalicylic acid (aspirin), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit cyclooxygenase and thus is not an anti-platelet agent.

Salsalate may reduce the Glycosylated hemoglobin A1c in patients with diabetes mellitus type 2.[1]

Drug toxicity

Tinnitus may happen, but is unlikely if the total daily dose is 3 grams or less.[1]

Gastrointestinal toxicity is less than with other non-steroidal anti-inflammatory agents.[2][3]

References

  1. 1.0 1.1 Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al. (2010). "The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.". Ann Intern Med 152 (6): 346-57. DOI:10.1059/0003-4819-152-6-201003160-00004. PMID 20231565. Research Blogging.
  2. Roth S, Bennett R, Caldron P, Hartman R, Mitchell C, Doucette M et al. (1990). "Reduced risk of NSAID gastropathy (GI mucosal toxicity) with nonacetylated salicylate (salsalate): an endoscopic study.". Semin Arthritis Rheum 19 (4 Suppl 2): 11-9. PMID 2181673[e]
  3. Lanza F, Rack MF, Doucette M, Ekholm B, Goldlust B, Wilson R (1989). "An endoscopic comparison of the gastroduodenal injury seen with salsalate and naproxen.". J Rheumatol 16 (12): 1570-4. PMID 2625689[e]